Lumen Technologies and 2 Other Stocks Under $2 Are Insider Buying – Lumen Technologies (NYSE:LUMN), Aclaris Therapeutics (NASDAQ:ACRS)

The Dow Jones index closed down more than 400 points on Tuesday. When insiders buy or sell shares, it indicates their confidence or concern about the company’s prospects. Investors and traders interested in penny stocks can consider this as a factor in their overall investment or trading decision.

Below is a look at some recent notable insider transactions for penny stocks. For more information, check it out Benzinga’s insider transactions platform.

Aclaris therapy

• The Commerce: Aclaris Therapeutics, Inc. ACRS Director Andrew Kenneth William Powell purchased a total of 14,500 shares an average price of $1.24. To acquire these shares, the cost was approximately $17,955.
• What is going on: Aclaris Therapeutics reported fourth quarter earnings results on February 27, 2024.
• What Aclaris Therapeutics does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the United States. It focuses on the development of new drug candidates for immunoinflammatory diseases.

Lumen Technologies

• The Commerce: Lumen Technologies, Inc. LUMONE Director Laurie Siegel acquired a total of 30,000 shares in at an average price of $1.60. To acquire these shares, the cost was approximately $47,997.
• What is going on: On March 1, Lumen Technologies named Ryan Asdourian as its new executive vice president and chief marketing officer.
• What Lumen Technologies does: With 450,000 miles of fiber, Lumen Technologies is one of the largest telecommunications operators in the United States serving global enterprises.

Check it: Campbell’s soup, box and 3 stocks to watch ahead of Wednesday

Personal

• The Commerce: Staff, Inc. PSNL Director Woodrow A Myers Jr purchased a total of 10,000 shares at an average price of $1.67. The insider spent about $16,700 to buy those shares.
• What is going on: On February 28, Personalis released disappointing quarterly results.
• What the staff do: Personalis Inc is a provider of genomic sequencing and analysis solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.

Don’t forget to check out our pre-market coverage here